LGT Capital Partners LTD. Sells 29,246 Shares of IDEXX Laboratories, Inc. $IDXX

LGT Capital Partners LTD. reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 120,325 shares of the company’s stock after selling 29,246 shares during the quarter. IDEXX Laboratories comprises about 3.7% of LGT Capital Partners LTD.’s portfolio, making the stock its 8th largest holding. LGT Capital Partners LTD.’s holdings in IDEXX Laboratories were worth $76,874,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in IDXX. J.Safra Asset Management Corp acquired a new position in IDEXX Laboratories during the third quarter valued at approximately $31,000. Armstrong Advisory Group Inc. increased its stake in shares of IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $35,000. Greykasell Wealth Strategies Inc. acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $35,000. Finally, WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent analyst reports. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Piper Sandler lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Down 2.0%

Shares of IDXX opened at $623.13 on Tuesday. The company has a market capitalization of $49.76 billion, a PE ratio of 47.68, a PEG ratio of 3.87 and a beta of 1.67. The stock’s 50-day moving average price is $676.19 and its two-hundred day moving average price is $669.13. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 18,180 shares of company stock worth $11,626,996 over the last three months. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.